Evidence map›Paper›PMID 35204409›Full record

ArticleDiagnostics (Basel, Switzerland)2022

Identification of Novel Diagnostic Markers for Malignant Pleural Mesothelioma Using a Reverse Translational Approach Based on a Rare Synchronous Tumor.

Tomoaki Naka, Yutaka Hatanaka, Yukiko Tabata, Akira Takasawa, Hideo Akiyama, Yasuhiro Hida, Hiromi Okada, Kanako C Hatanaka, Tomoko Mitsuhashi, Kei Kushitani and 5 more

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Diagnostics (Basel, Switzerland), 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact, top 99% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed, 0 citations in OpenAlex.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

15 authors at 4 institutions in 1 country.

Tomoaki NakaDepartment of Surgical Pathology, Hokkaido University Hospital, Sapporo 060-8648, Japan.
Yutaka HatanakaDepartment of Surgical Pathology, Hokkaido University Hospital, Sapporo 060-8648, Japan.ORCID 0000-0003-3128-1477
Yukiko TabataDepartment of Surgical Pathology, Hokkaido University Hospital, Sapporo 060-8648, Japan.
Akira TakasawaDepartment of Surgical Pathology, Hokkaido University Hospital, Sapporo 060-8648, Japan.
Hideo AkiyamaResearch Division of Genome Companion Diagnostics, Hokkaido University Hospital, Sapporo 060-8648, Japan.
Yasuhiro HidaDepartment of Cardiovascular and Thoracic Surgery, Graduate School of Medicine, Hokkaido University, Sapporo 060-8638, Japan.ORCID 0000-0003-1759-4215
Hiromi OkadaDepartment of Surgical Pathology, Hokkaido University Hospital, Sapporo 060-8648, Japan.
Kanako C HatanakaDepartment of Surgical Pathology, Hokkaido University Hospital, Sapporo 060-8648, Japan.
Tomoko MitsuhashiDepartment of Surgical Pathology, Hokkaido University Hospital, Sapporo 060-8648, Japan.
Kei KushitaniDepartment of Pathology, Graduate School of Biomedical and Health Sciences, Hiroshima University, Hiroshima 734-8551, Japan.
Vishwa Jeet AmatyaDepartment of Pathology, Graduate School of Biomedical and Health Sciences, Hiroshima University, Hiroshima 734-8551, Japan.
Yukio TakeshimaDepartment of Pathology, Graduate School of Biomedical and Health Sciences, Hiroshima University, Hiroshima 734-8551, Japan.
Kouki InaiDepartment of Pathology, Graduate School of Biomedical and Health Sciences, Hiroshima University, Hiroshima 734-8551, Japan.
Kichizo KagaDepartment of Cardiovascular and Thoracic Surgery, Graduate School of Medicine, Hokkaido University, Sapporo 060-8638, Japan.
Yoshihiro MatsunoDepartment of Surgical Pathology, Hokkaido University Hospital, Sapporo 060-8648, Japan.
Hokkaido University · JPHokkaido University Hospital · JPHiroshima University · JPToray Industries, Inc. (Japan) · JP

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Although the routine use of immunohistochemistry has improved the accuracy of histopathologic diagnosis in clinical practice, new methods for discovering novel diagnostic markers are still needed. We sought new diagnostic markers for malignant pleural mesothelioma (MPM) using a reverse translational approach with limited archival tissues from a very rare case. Total RNA extracted from formalin-fixed paraffin-embedded (FFPE) tissues of a synchronous collision tumor consisting of MPM and pulmonary adenocarcinoma (PAC) was employed for gene expression profiling (GEP) analysis. Among the 54 genes selected by GEP analysis, we finally identified the following two candidate MPM marker genes:

Indexed as

gene expression profilingimmunohistochemistrymalignant pleural mesothelioma

Identifiers

PMID35204409
PMCPMC8871196
OpenAlexW4210326265

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.